Moderna’s Phase 1 dose escalation research trial is evaluating the safety and tolerability of mRNA-2752 administered alone and in combination with durvalumab for patients with advanced or metastatic solid tumor malignancies or lymphoma.

As a health care provider (HCP) who sees adult patients with advanced or metastatic solid tumor malignancies or lymphoma, you are invited to participate in the Effectus Patient Identification and Consultation Program to help identify candidates for the Moderna mRNA-2752-P101 trial. You will be asked to consult with patients in a neutral manner about the trial and assess their interest in participating at a nearby trial site. Patients may be able to take part if they are 18 years of age or older and meet additional high-level criteria (key trial criteria will be provided to you upon onboarding). At the trial site, patients will undergo trial screening to determine eligibility.

Compensation at fair market value will be available for HCPs who participate and meet program requirements.

Effectus will be your trusted partner throughout your participation, helping to facilitate your patients to the trial site and thus relieving the burden on your practice. If you wish to participate, you will be asked to review and sign a Services Agreement with Effectus, which outlines your program responsibilities and compensation. Participation is completely voluntary, and you can opt out at any time. Background on the trial, program materials, and program logistics will be reviewed in detail during a 1-hour virtual training session.

The Moderna mRNA-2752-P101 trial provides an opportunity to contribute to the research and advancement of a potential new treatment option for patients with advanced or metastatic solid tumor malignancies or lymphoma. The trial also allows HCPs the opportunity to offer alternative treatment options to their patients.